Amarin Investors Want 3rd Circ. To Revive Heart Drug Suit
Investors who poured money into heart-drug maker Amarin Corp. PLC urged the Third Circuit to revive their lawsuit accusing the company and its officials of concealing clinical trial issues that led...To view the full article, register now.
Already a subscriber? Click here to view full article